News Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.96 ^USD	+1.37%		-1.66%	+23.33%

May. 15	Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	MT
May. 15	Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	May. 15	MT
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	May. 15	AQ
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	May. 15	CI
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	May. 02	AQ
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	May. 02	CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	May. 01	MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	Apr. 30	CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00	Apr. 29	MT
Immutep Quarterly Activities Report Q3 FY24	Apr. 29	AQ
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	Apr. 25	CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	Apr. 24	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	Apr. 24	CI
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	Apr. 18	AQ
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	Apr. 18	CI
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	Apr. 18	PU
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	Apr. 18	MT
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	Apr. 17	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17	AQ
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17	CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	Apr. 17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Summary

Filters